# Career Project Brainstorm — Targeting Bioptimus & AI-Bio Roles

**Date**: April 2026  
**Target**: Bioinformatics / Data Analytics / Computational Biology roles  
**Reference company**: Bioptimus (Paris) — building foundation models for biology  
**Your background**: Cancer biology, EMT, cancer therapeutics, biomarker studies, immunotherapy  

---

## 1. What Bioptimus Actually Does (Intelligence Gathered)

| Model / Initiative | What it is | Why it matters |
|---|---|---|
| **H-Optimus-1** | Foundation model for histology/pathology (1B+ params, 1M+ WSI trained) | #1 ranked pathology AI; 1M+ downloads; used by 16/20 top pharma |
| **M-Optimus** | World model of biology — multimodal (H&E + spatial transcriptomics + bulk RNA + clinical) | Predicts gene mutations, clinical outcomes, cell composition from H&E alone |
| **STELA** | Spatial Tissue Embedding Learning Atlas — 100,000 patient specimens, Xenium (10x Genomics) + Broad Clinical Labs | Largest clinically linked spatial biology atlas; data backbone for M-Optimus |

**Core problems they solve:**
- Predict gene expression / mutation status from routine H&E (cheap test → expensive insight)
- Patient stratification for clinical trials using multimodal embeddings
- Drug target discovery through AI "deep mining" of biological patterns
- Spatial mapping of disease biology (tumor microenvironment, immune infiltration)

**Skills they value:** Spatial transcriptomics · Digital pathology · Multimodal ML · Biomarker discovery · scRNA-seq · Clinical data integration · Foundation models (PyTorch, Transformers)

---

## 2. Your Competitive Advantage (Why You're Perfect)

```
Your Biology Background          →    Maps to Bioptimus Focus
─────────────────────────────────────────────────────────────────
EMT research                     →    Spatial EMT mapping in tumors (STELA use case)
Cancer biology                   →    Oncology is their primary indication
Biomarker studies                →    Biomarker discovery is their core product
Immunotherapy                    →    Immune TME prediction, immunotherapy response
Cancer therapeutics              →    Drug target discovery, combination strategies
scRNA-seq (this project)         →    M-Optimus integrates scRNA-seq modality
AI agent workflows (built here)  →    They deploy LLM agents for "deep mining"
```

**Your unique story:** *"I study EMT and tissue fluidity — the exact process by which cancer cells become migratory and invasive. I've built AI agent systems to analyze this at single-cell resolution, and now I'm extending this to spatial and multimodal contexts."*

---

## 3. Projects — EASY Level

> **Goal:** Demonstrate core bioinformatics + data analytics skills. Complete in 1–2 weeks.  
> **AI agents:** Use this workspace's existing agent framework.

---

### E1. Multi-Cancer EMT Biomarker Atlas
**What:** Analyze 5+ public cancer scRNA-seq datasets (GEO), score EMT signatures, compare across cancer types.  
**AI agents:** `data-wrangler` auto-downloads GEO data → `scrna-analyst` clusters + scores → `visualization-specialist` makes figures  
**Output:** Interactive dashboard (FastAPI + React, reuse `dashboard/` from this project) + publication-quality UMAP figures  
**Data:** GEO: GSE131907 (lung cancer), GSE132465 (CRC), GSE110686 (breast), GSE144735 (pancreatic)  
**Tech stack:** Python 3.10, Scanpy, seaborn, FastAPI, React  
**Interview hook:** *"I built a cross-cancer EMT atlas using AI agents — each agent handled a stage (download, QC, scoring, visualization) autonomously."*  
**Bioptimus connection:** Biomarker discovery pipeline; shows you can work with multi-dataset integration

```
Difficulty:  ██░░░░░░░░  (2/10)
Time:        1–2 weeks
Impact:      High — demonstrates your core expertise + AI agents
```

---

### E2. H-Optimus Tumor Microenvironment Explorer
**What:** Use Bioptimus's H-Optimus-0 (free on HuggingFace) to extract embeddings from TCGA pathology slides. Cluster patches, identify tumor/stroma/immune regions.  
**AI agents:** Agent fetches slides from GDC portal → embedding extraction → clustering → report generation  
**Output:** Annotated whole-slide image viewer + embedding UMAP  
**Data:** TCGA-BRCA or TCGA-LUAD (public via GDC Data Portal)  
**Tech stack:** Python, `timm` (H-Optimus model), OpenSlide, scikit-learn, UMAP  
**Interview hook:** *"I directly evaluated your H-Optimus model on public TCGA data — here's what I found about tumor microenvironment structure."*  
**Bioptimus connection:** You are literally using their product and contributing feedback

```
Difficulty:  ███░░░░░░░  (3/10)
Time:        1–2 weeks
Impact:      Very High — shows you know their tech and can evaluate it critically
```

```python
# Quick start — load H-Optimus-0 from HuggingFace
import timm
model = timm.create_model("hf-hub:bioptimus/H-optimus-0", pretrained=True, init_values=1e-5, dynamic_img_size=False)
model.eval()
# Extract embeddings from patches, then UMAP cluster them
```

---

### E3. Cancer Biomarker Report Generator (AI Agent)
**What:** An AI agent that takes a gene list (e.g., EMT markers) and automatically: queries GEO → downloads matching datasets → runs DE analysis → generates a PDF report  
**Tech stack:** Python, LangChain or CrewAI, GEOparse, Scanpy, ReportLab  
**Output:** Automated PDF biomarker reports  
**Interview hook:** *"I built an autonomous agent that discovers and validates biomarkers across public datasets without manual intervention."*

```
Difficulty:  ███░░░░░░░  (3/10)
Time:        1 week
Impact:      Medium — demonstrates AI agent engineering + bioinformatics
```

---

## 4. Projects — MEDIUM Level

> **Goal:** Demonstrate analytical depth, ML skills, and integration. Complete in 2–4 weeks.

---

### M1. Spatial Transcriptomics EMT Mapping in Cancer Tumors
**What:** Download public 10x Xenium/Visium cancer data, spatially map EMT programs, identify EMT-high invasion fronts, correlate with histology features.  
**AI agents:** Full pipeline orchestration — from data download to spatial DE to figure generation  
**Data:** 10x Genomics public datasets (Xenium FFPE Human Breast Cancer), or GEO Visium datasets  
**Tech stack:** Python, Scanpy, Squidpy (spatial analysis), matplotlib  
**Output:**
- Spatial EMT score maps overlaid on tissue sections
- Cell-cell communication at invasion fronts (CellChat)
- Comparison: wound healing EMT (your current project) vs. cancer EMT

**Interview hook:** *"I mapped EMT programs spatially in breast cancer — the invasion front shows a stereotyped EMT gradient I could quantify."*  
**Bioptimus connection:** STELA is built on Xenium; spatial transcriptomics is their current biggest bet

```
Difficulty:  █████░░░░░  (5/10)
Time:        2–3 weeks
Impact:      Very High — directly relevant to STELA project
```

---

### M2. Immunotherapy Response Predictor from TME Composition
**What:** Download scRNA-seq from immunotherapy clinical trials → deconvolve TME → train ML classifier to predict responders vs. non-responders. Use SHAP for biomarker interpretation.  
**Data:**  
- GSE123813 (anti-PD1 in melanoma, scRNA-seq, known responders)  
- GSE200996 (pembrolizumab in lung cancer)  
- TCGA bulk + clinical for validation

**ML pipeline:**
```
scRNA-seq reference → TME deconvolution of bulk RNA → 
Feature matrix (cell type fractions + signature scores) → 
XGBoost/Random Forest → Predict response →
SHAP analysis → Biomarker shortlist
```

**AI agents:** `de-analyst` for per-cell-type signatures → `data-wrangler` for TCGA clinical data → ML agent for training + SHAP  
**Output:** Biomarker panel + validation AUC curve + clinical outcome forest plot  
**Interview hook:** *"I built a treatment response predictor using TME cell composition as features — the top predictors align with published anti-PD1 biomarkers."*  
**Bioptimus connection:** M-Optimus predicts ORR; your project demonstrates the concept with real data

```
Difficulty:  █████░░░░░  (5/10)
Time:        3–4 weeks
Impact:      Extremely High — clinical + ML + your immunotherapy expertise
```

---

### M3. Pseudobulk EMT Longitudinal Atlas (This Project Extended)
**What:** Extend your current wound healing project — add temporal EMT trajectory analysis and compare EMT dynamics in wound healing vs. cancer invasion (cross-disease comparison).  
**Already have:** GSE234269 (wound healing scRNA-seq)  
**Add:** Cancer invasion scRNA-seq (GEO) as EMT reference  
**New analysis:**
- Pseudotime + RNA velocity for EMT trajectory
- Transfer learning: wound healing EMT → cancer EMT scoring
- Regulon analysis (SCENIC) — which TFs drive each EMT state

**AI agents:** Extend existing pipeline with new agents  
**Bioptimus connection:** Cross-scale biological insight (molecules → tissue); exactly the kind of integrative analysis M-Optimus aims to automate

```
Difficulty:  █████░░░░░  (5/10)
Time:        2–3 weeks (builds on existing work!)
Impact:      High — deepens your existing project with publishable analysis
```

---

### M4. Cell Deconvolution Benchmarking Tool
**What:** Compare bulk RNA deconvolution methods (CIBERSORT, BayesPrism, Scaden, CellChat) using your scRNA-seq data as ground truth. Build a standardized benchmarking pipeline.  
**Why:** Deconvolution is a key step in translating scRNA-seq findings to bulk clinical cohorts (TCGA); quality benchmarking is needed for clinical-grade tools  
**Output:** Benchmarking report + recommended pipeline for EMT/immune deconvolution  
**Interview hook:** *"I rigorously compared deconvolution methods and identified which is most accurate for tumor microenvironment — key for clinical biomarker translation."*

```
Difficulty:  ████░░░░░░  (4/10)
Time:        2 weeks
Impact:      Medium-High — shows analytical rigor and methods awareness
```

---

## 5. Projects — HARD Level

> **Goal:** Demonstrate AI/ML research capability, multimodal integration, and production-level thinking.  
> **Timeline:** 4–8 weeks each.

---

### H1. Histology-to-Transcriptomics Bridge (Mini M-Optimus)
**What:** Use H-Optimus-1 embeddings from matched H&E patches to predict spatial gene expression (EMT genes, immune markers) — replicating the core M-Optimus concept at small scale.  
**Data:**
- TCGA-BRCA: H&E slides + bulk RNA (matched)  
- OR: Public Visium datasets with matched H&E (10x Genomics website)
  
**Pipeline:**
```
H&E WSI → Patch extraction (256×256, 20x) →
H-Optimus-1 embedding (1024-dim per patch) →
Regression model (Ridge/MLP/attention) →
Predict: EMT score, CD8 T-cell fraction, VEGF expression

Validation: Pearson correlation vs. actual spatial transcriptomics
```

**Output:** Prediction maps overlaid on H&E + HEST benchmark score (standard in field)  
**Interview hook:** *"I replicated your core M-Optimus concept — predicting gene expression from H&E — using your H-Optimus-1 model, and achieved X Pearson correlation on HEST benchmark."*  
**Bioptimus connection:** This IS their product. You have hands-on validation experience with their tech.

```python
# Key libraries
# pip install openslide-python timm torch torchvision huggingface_hub
# HEST library: pip install hest  (standard benchmark for this task)
```

```
Difficulty:  ████████░░  (8/10)
Time:        4–6 weeks
Impact:      Exceptional — directly demonstrates Bioptimus's core technology
```

**Resources:**
- HEST-1k benchmark: https://github.com/mahmoodlab/HEST (H&E + Visium matched dataset)
- H-Optimus-1 docs: https://docs.bioptimus.com/

---

### H2. Multimodal Cancer Intelligence Platform (Mini STELA)
**What:** Build an end-to-end multimodal biomarker platform integrating:
1. scRNA-seq (cell type composition, EMT/immune signatures)
2. Bulk RNA-seq deconvolution (TCGA cohort)  
3. Clinical outcomes (survival, treatment response)
4. Optional: H-Optimus embeddings from matched H&E

**AI agent architecture:**
```
┌─────────────────────────────────────────────────────┐
│                  ORCHESTRATOR AGENT                  │
├──────────┬─────────────────┬────────────────────────┤
│data-     │ scRNA           │ clinical               │
│wrangler  │ analyst         │ analyst                │
│(GEO+TCGA)│ (Scanpy)        │ (survival ML)          │
├──────────┴─────────────────┴────────────────────────┤
│         INTEGRATION LAYER (multimodal embedding)     │
├─────────────────────────────────────────────────────┤
│         REPORT AGENT (auto-generate findings)        │
└─────────────────────────────────────────────────────┘
```

**Output:**
- Patient stratification model (AUC > 0.75 target)
- Interpretable biomarker panel (top 10 genes + cell types)
- Interactive dashboard (reuse dashboard/ from this workspace)
- Methods section auto-generated by `report-writer` agent

**Interview hook:** *"I built a miniature version of STELA — integrating scRNA-seq, bulk RNA, and clinical data to predict immunotherapy outcomes. My AI agent system orchestrated the entire pipeline."*

```
Difficulty:  █████████░  (9/10)
Time:        6–8 weeks
Impact:      Exceptional — portfolio centerpiece for AI-bio companies
```

---

### H3. AI Agent for Clinical Trial Patient Stratification
**What:** Build an autonomous AI agent system that:
1. Takes a cancer type + therapeutic target as input
2. Mines public scRNA-seq + TCGA data for molecular features
3. Trains a stratification model (which patients have the right molecular profile)
4. Generates synthetic control arms from historical data
5. Outputs a clinical trial design report

**Agent framework:** LangChain / AutoGen / CrewAI  
**LLM backbone:** GPT-4o or Claude (via API) for reasoning  
**Bioinformatics tools:** Scanpy, R/DESeq2 (via subprocess), survival analysis (lifelines)

**Example workflow:**
```
User: "Design a trial for EGFR inhibitor in lung adenocarcinoma"
→ Agent 1: Query GEO + TCGA for EGFR-high LUAD
→ Agent 2: Score EMT, immune infiltration, biomarker panels
→ Agent 3: Identify inclusion/exclusion biomarkers
→ Agent 4: Generate synthetic control arm from historical data
→ Agent 5: Write trial design report
```

**Interview hook:** *"This is what M-Optimus does at scale — I built a proof-of-concept AI agent that designs clinical trial stratification strategies from biological data."*

```
Difficulty:  █████████░  (9/10)
Time:        6–8 weeks
Impact:      Transformative — directly replicates M-Optimus's clinical use case
```

---

## 6. Quick Wins — Skills to Learn for Bioptimus-Type Roles

| Skill | Priority | Resource | Time |
|---|---|---|---|
| Spatial transcriptomics (Squidpy, Visium/Xenium) | CRITICAL | 10x Genomics tutorials + Scanpy spatial | 1 week |
| Digital pathology (OpenSlide, patch extraction) | HIGH | CLAM repo tutorial | 3 days |
| H-Optimus API usage | HIGH | docs.bioptimus.com | 1 day |
| HEST benchmark | HIGH | github.com/mahmoodlab/HEST | 2 days |
| Multimodal ML (attention, late fusion) | HIGH | PyTorch tutorials | 2 weeks |
| Survival analysis (Kaplan-Meier, Cox) | MEDIUM | lifelines Python library | 1 week |
| SHAP / model explainability | MEDIUM | shap library tutorial | 3 days |
| Docker + cloud deployment (AWS SageMaker) | MEDIUM | H-Optimus is on SageMaker | 1 week |

---

## 7. Recommended Project Order

```
Month 1 (Build Foundation)
├── E2: H-Optimus TME Explorer ←── Start here! Uses their model directly
├── E1: Multi-Cancer EMT Atlas ←── Leverages your expertise
└── Learn: Spatial transcriptomics fundamentals

Month 2 (Go Deeper)
├── M1: Spatial EMT Mapping ←── Visium/Xenium, direct STELA connection
├── M2: Immunotherapy Response Predictor ←── Your clinical expertise shines
└── M3: Extend wound healing project with cross-disease comparison

Month 3 (Portfolio Centerpiece)
├── H1: Histology-to-Transcriptomics Bridge ←── THE key project
└── H2: Multimodal Cancer Platform ←── Full-stack AI-bio

Month 4 (Advanced / Optional)
└── H3: Clinical Trial AI Agent ←── If targeting senior roles
```

---

## 8. The Interview Story Arc

### For a Bioinformatics role:
> "I come from cancer biology — EMT, immunotherapy, biomarkers. When I transitioned to computational work, I started with scRNA-seq for wound healing and tissue fluidity — which maps directly to cancer invasion. I built an AI agent system for the entire analysis pipeline. Then I extended this to spatial transcriptomics, mapping EMT spatially in tumors using Xenium data. Finally, I used H-Optimus-1 to predict gene expression from H&E — essentially replicating the approach M-Optimus uses at scale."

### For a Data Analytics role:
> "I've built automated pipelines that go from raw sequencing data to clinical insight — using AI agents to orchestrate each analytical step. I validated my findings against known biomarkers, built interactive dashboards for exploration, and produced publication-quality outputs. My background in immunotherapy gives me the biological intuition to know which signals matter."

### Key talking points at Bioptimus:
- "I used H-Optimus-1 and benchmarked it on [specific task]" ← uses their product
- "I built a spatial transcriptomics pipeline directly relevant to STELA" ← their current focus  
- "My EMT research maps directly to cancer invasion and treatment resistance" ← clinical relevance
- "I architected multi-agent AI systems for automated biological analysis" ← their agent deployment vision

---

## 9. GitHub Portfolio Structure (Suggested)

```
github.com/rahulsarate/
├── scRNA-seq-for-tissue-fluidity/     ← existing (wound healing + EMT + agents)
├── cancer-emt-atlas/                   ← E1: Multi-cancer EMT dashboard
├── h-optimus-tme-explorer/             ← E2: Using Bioptimus's model
├── spatial-emt-cancer/                 ← M1: Spatial transcriptomics  
├── immunotherapy-response-ml/          ← M2: Clinical ML
└── histology-transcriptomics-bridge/   ← H1: THE flagship project
```

Each repo should have:
- `README.md` with a one-paragraph biological motivation, then methods, then results
- Reproducible pipeline (Snakemake or scripts + conda env)
- Example outputs (figures, tables) — even if synthetic data
- DON'T commit large files (follow existing .gitignore patterns)

---

## 10. Other Companies to Target (Similar to Bioptimus)

| Company | Focus | Your angle |
|---|---|---|
| **Owkin** (Paris/NYC) | Federated learning for clinical data | EMT biomarkers + federated ML |
| **PathAI** | Pathology AI | H-Optimus experience + cancer biology |
| **Tempus AI** | Clinical + genomics data | Biomarker + clinical analytics |
| **Foundation Medicine** | Cancer genomics + biomarkers | Your biomarker experience directly |
| **10x Genomics** | Spatial biology tools | Xenium spatial analysis projects |
| **Genentech/Roche** | Cancer immunotherapy + omics | IMvigor, anti-PD-L1 datasets |
| **Recursion** | AI drug discovery | Agent-based molecular analysis |
| **CellDynamics / LifeArc** | Translational biology + AI | Wet lab + computational combo |
| **Immunoscape** | Immune profiling | Your immunotherapy background |

---

## 11. NEW Projects — Next-Generation Skills (Added April 17, 2026)

> **Goal:** Fill portfolio gaps in foundation models, perturbation biology, multi-omics, and graph ML.  
> **These complement, not replace, the projects above.**

---

### N1. Single-Cell Foundation Model Fine-Tuning (scGPT / Geneformer)
**What:** Fine-tune an open-source single-cell foundation model on wound healing + cancer EMT data to create a specialized EMT cell-state classifier.  
**Why this matters:** Foundation models for single-cell (scGPT, Geneformer, scBERT) are the next frontier — Bioptimus's M-Optimus integrates single-cell embeddings. Showing you can fine-tune these models is a massive differentiator.  
**Data:**
- Your wound healing dataset (GSE234269) — already processed
- Cancer EMT reference: GSE131907 (lung cancer scRNA-seq, ~200k cells)
- Optional: Tabula Muris as pre-training validation

**Pipeline:**
```
Pre-trained scGPT/Geneformer (HuggingFace) →
Fine-tune on wound healing + cancer scRNA-seq →
Task 1: Cell type classification (zero-shot vs. fine-tuned)
Task 2: EMT state prediction (epithelial / partial-EMT / mesenchymal)
Task 3: Gene program discovery (attention-based feature importance)

Evaluation: Compare vs. Scanpy/Leiden clustering + manual annotation
```

**Tech stack:** Python, PyTorch, HuggingFace Transformers, Scanpy, Flash Attention  
**Output:**
- Fine-tuned model weights (HuggingFace Hub)
- Benchmark: accuracy on cell type + EMT state classification
- Attention heatmaps showing which genes drive EMT classification
- Blog post / README walkthrough

**Interview hook:** *"I fine-tuned scGPT on wound healing and cancer data — the model learned EMT states that match known biology, and the attention weights revealed novel gene interactions."*  
**Bioptimus connection:** M-Optimus uses foundation model embeddings from scRNA-seq; you've demonstrated you can work at this level

```python
# Quick start — scGPT from HuggingFace
# pip install scgpt flash-attn transformers
from scgpt.model import TransformerModel
from scgpt.tokenizer import GeneVocab

# Load pre-trained, then fine-tune on your EMT-labeled cells
```

```
Difficulty:  ██████░░░░  (6/10)
Time:        2–3 weeks
Impact:      Exceptional — very few candidates have fine-tuned single-cell FMs
```

---

### N2. Perturbation Prediction with CPA / GEARS
**What:** Use public Perturb-seq data (CRISPR knockdowns + scRNA-seq readout) to train a model that predicts how cells respond to gene perturbations — then predict: "What happens to EMT if we knock down Snai1 in fibroblasts?"  
**Why this matters:** Perturbation biology is the next $10B market. Bioptimus, Recursion, and Cellarity all invest here. Predicting cellular response to perturbation from foundation model embeddings is a key M-Optimus use case.  
**Data:**
- Replogle et al. 2022 — K562 CRISPRi Perturb-seq (~1000 gene KOs, ~2.5M cells) — public on GEO
- Norman et al. 2019 — combinatorial perturbations (for multi-gene prediction)
- Your wound healing data — as the "target" for transfer predictions

**Pipeline:**
```
Perturb-seq reference data (K562) →
Train CPA (Compositional Perturbation Autoencoder) or GEARS (GNN-based) →
Predict: single-gene KO effects on EMT genes (Snai1, Zeb1, Twist1) →
Validate: compare predicted vs. actual KO effects from published literature →
Transfer: predict wound healing cell responses to therapeutic perturbations
```

**Tech stack:** Python, PyTorch, scvi-tools (CPA), GEARS, Scanpy  
**Output:**
- Perturbation response predictions for EMT regulators
- Validated against known biology (e.g., Snai1 KO → E-cadherin upregulation)
- Drug target ranking: which perturbations most shift cells from mesenchymal → epithelial?

**Interview hook:** *"I built a perturbation prediction model — given any gene knockout, I can predict the transcriptomic response. I used this to rank drug targets that reverse EMT in wound healing."*  
**Bioptimus connection:** Perturbation prediction from embeddings is a stated M-Optimus roadmap item

```python
# GEARS — Graph-based perturbation prediction
# pip install gears
from gears import PertData, GEARS

pert_data = PertData('./data')
pert_data.load(data_name='norman')  # Norman et al. combinatorial perturbations
model = GEARS(pert_data, device='cuda')
model.model_initialize(hidden_size=64)
model.train(epochs=20)
# Predict unseen perturbation combos
```

```
Difficulty:  ███████░░░  (7/10)
Time:        3–4 weeks
Impact:      Exceptional — cutting-edge computational biology
```

**Resources:**
- CPA: https://github.com/theislab/cpa
- GEARS: https://github.com/snap-stanford/GEARS
- Replogle data: GEO GSE132080

---

### N3. Multi-Omic Integration: scRNA + scATAC
**What:** Integrate scRNA-seq with scATAC-seq (chromatin accessibility) to identify which transcription factor binding sites are open during EMT transitions. This adds the epigenomic layer to your EMT story.  
**Why this matters:** Gene expression alone can't tell you *why* a gene is on — you need chromatin context. Bioptimus's multimodal approach explicitly includes epigenomics. This project shows you think beyond transcriptomics.  
**Data:**
- 10x Multiome (scRNA + scATAC from same cell) public datasets
- SHARE-seq skin data (Ma et al. 2020, *Cell*) — skin + hair follicle, directly relevant to wound healing
- PBMC multiome (10x Genomics website) — for pipeline validation

**Pipeline:**
```
scRNA-seq + scATAC-seq (paired) →
WNN integration (Seurat v5) or MOFA+ (Python) →
Identify: TF motifs enriched in open chromatin of EMT-high cells →
Link: enhancer accessibility → target gene expression (peak-gene links) →
Output: EMT regulatory network (TF → enhancer → target gene)
```

**Tech stack:**
- R: Seurat v5 (WNN), Signac, chromVAR, ArchR
- Python: muon, SnapATAC2, SCENIC+ (TF regulon + chromatin)
- Visualization: ComplexHeatmap, genome browser tracks (pyGenomeTracks)

**Output:**
- Multimodal UMAP (RNA + ATAC weighted)
- TF motif enrichment in EMT states (JASPAR database)
- Peak-to-gene linkage map for EMT regulators
- Chromatin accessibility tracks at EMT loci (Vim, Cdh1, Snai1)

**Interview hook:** *"I showed that Snai1's binding sites become accessible 3 days post-wounding — before Snai1 mRNA is even detectable — proving that chromatin priming precedes EMT transcription."*  
**Bioptimus connection:** Multimodal data integration is the core of M-Optimus; epigenomics is a stated future modality

```
Difficulty:  ██████░░░░  (6/10)
Time:        3–4 weeks
Impact:      Very High — adds a whole new data modality to your portfolio
```

---

### N4. Graph Neural Network for Gene Regulatory Networks
**What:** Build a GNN that takes a gene regulatory network (GRN) as input and predicts: (a) which TFs are master regulators of EMT, (b) which edges (TF→target) are active in each wound healing phase.  
**Why this matters:** Bioptimus uses graph representations internally for M-Optimus. GNN + biology is a rare skill combination. Most biologists can't build GNNs; most ML engineers don't know biology. You bridge both.  
**Data:**
- GRN from SCENIC/pySCENIC (already available from your pipeline)
- Node features: gene expression per cell type per condition
- Edge features: TF-target correlation, motif score
- Ground truth: known EMT TF hierarchies from literature

**Pipeline:**
```
pySCENIC → GRN (TF → target edges with importance scores) →
Build graph: nodes = genes, edges = regulatory links →
GNN (GraphSAGE or GAT) →
Task 1: Node classification — predict EMT role (driver / passenger / repressor)
Task 2: Edge prediction — which TF→target links activate at wound_3d vs wound_14d?
Task 3: Graph-level — classify wound phase from GRN topology alone

Validation: Known EMT master regulators (Snai1, Twist1, Zeb1) should rank top
```

**Tech stack:** Python, PyTorch Geometric (PyG), NetworkX, pySCENIC, Scanpy  
**Output:**
- Trained GNN with EMT TF rankings
- Dynamic GRN visualization (wound phase animation)
- Novel TF predictions validated against literature
- Graph attention weights → interpretable regulatory logic

**Interview hook:** *"I trained a graph neural network on gene regulatory networks from wound healing — it correctly identified Snai1 and Twist1 as master EMT regulators and predicted novel candidates."*  
**Bioptimus connection:** Graph-based molecular representations are used in M-Optimus for drug target discovery

```python
# PyTorch Geometric — GNN for GRN
import torch
from torch_geometric.nn import GATConv
from torch_geometric.data import Data

# Build graph from SCENIC output
# nodes: genes (features = expression vector)
# edges: TF → target (features = importance score)
class GRN_GNN(torch.nn.Module):
    def __init__(self, in_channels, hidden, out_channels):
        super().__init__()
        self.conv1 = GATConv(in_channels, hidden, heads=4)
        self.conv2 = GATConv(hidden * 4, out_channels, heads=1)
    def forward(self, x, edge_index):
        x = self.conv1(x, edge_index).relu()
        return self.conv2(x, edge_index)
```

```
Difficulty:  ████████░░  (8/10)
Time:        3–4 weeks
Impact:      Exceptional — rare skill combo (GNN + single-cell biology)
```

---

### N5. Clinical NLP: Mining Pathology Reports for EMT Features
**What:** Extract EMT-related morphological features (invasion pattern, tumor budding, stromal reaction) from free-text TCGA pathology reports using NLP, then correlate with your scRNA-seq EMT signatures.  
**Why this matters:** Bioptimus's M-Optimus generates pathology-grade reports from H&E. Showing you can parse, structure, and analyze clinical text — and link it to molecular data — demonstrates the full clinical-computational loop.  
**Data:**
- TCGA pathology reports (free text, available via GDC API)
- Focus: TCGA-BRCA, TCGA-COAD (breast + colorectal — high EMT relevance)
- Matched bulk RNA-seq for EMT signature scoring

**Pipeline:**
```
TCGA pathology reports (PDF/text) →
NLP extraction (BioBERT / PubMedBERT / regex patterns) →
Structured features: invasion_type, tumor_budding_score, stromal_reaction, grade →
Correlate with: bulk RNA EMT score (from Scanpy signatures) →
ML model: predict EMT_high vs EMT_low from pathology text features alone

Validation: EMT-high tumors should correlate with "infiltrative border", 
"high tumor budding", "desmoplastic stroma" in reports
```

**Tech stack:** Python, HuggingFace Transformers (BioBERT), spaCy, scikit-learn, GDC API  
**Output:**
- Structured pathology feature database (~1000 patients)
- NLP model performance (F1, AUC for EMT classification from text)
- Correlation matrix: text features vs. molecular EMT scores
- Clinical insight: which pathologist descriptions predict molecular EMT state?

**Interview hook:** *"I mined 1000 pathology reports and showed that 'tumor budding' in free text predicts high molecular EMT scores — linking clinical observations to single-cell biology."*  
**Bioptimus connection:** M-Optimus generates clinical reports; your NLP pipeline shows you understand the text-to-biology bridge from the other direction

```
Difficulty:  █████░░░░░  (5/10)
Time:        2–3 weeks
Impact:      High — unique NLP + biology angle that few candidates have
```

---

### N6. scVI Deep Generative Model for Batch Correction + Latent Discovery
**What:** Replace standard Scanpy preprocessing (normalize → HVG → PCA → UMAP) with scVI's variational autoencoder. Compare latent spaces, discover batch-corrected EMT programs, and use the decoder for gene imputation.  
**Why this matters:** scVI (Lopez et al., *Nature Methods*) is the gold standard for probabilistic scRNA-seq analysis. Bioptimus's internal tools are VAE-adjacent. Showing fluency with deep generative models signals ML maturity beyond "I can run Scanpy."  
**Data:**
- Your wound healing dataset (GSE234269) — 8 samples, batch effects expected between replicates
- Multi-study integration: combine with GSE159827 + GSE188432 (3 datasets, severe batch effects)

**Pipeline:**
```
Raw counts (no normalization!) →
scVI model (VAE with negative binomial likelihood) →
Latent space (10–30 dims) → UMAP →
Compare: scVI latent vs. standard PCA → which gives better cell type separation?
Differential expression: scVI's built-in Bayes factor DE (no pseudobulk needed)
Imputation: decode latent → imputed gene expression → better fluidity scores?
```

**Tech stack:** Python, scvi-tools, Scanpy, PyTorch, matplotlib  
**Output:**
- Side-by-side UMAP: standard pipeline vs. scVI
- Batch correction metrics (kBET, LISI scores)
- scVI differential expression results vs. pseudobulk DESeq2
- Imputed expression for low-dropout EMT genes

**Interview hook:** *"I compared standard scRNA-seq pipelines with deep generative models — scVI's latent space revealed an EMT intermediate state that PCA-based analysis missed."*  
**Bioptimus connection:** Deep generative models are the backbone of foundation model architectures; this shows you understand the ML fundamentals

```python
# scVI — 10 lines to a trained model
import scvi
import scanpy as sc

adata = sc.read_h5ad("wound_adata.h5ad")
scvi.model.SCVI.setup_anndata(adata, layer="counts", batch_key="sample_id")
model = scvi.model.SCVI(adata, n_latent=30, gene_likelihood="nb")
model.train(max_epochs=200, early_stopping=True)

# Get latent representation
adata.obsm["X_scVI"] = model.get_latent_representation()
sc.pp.neighbors(adata, use_rep="X_scVI")
sc.tl.umap(adata)
```

```
Difficulty:  ████░░░░░░  (4/10)
Time:        1–2 weeks
Impact:      High — shows deep ML understanding beyond standard pipelines
```

---

## 12. Strategic Additions

### Open Source Contributions (High Signal, Low Effort)
Contributing to open-source tools used by Bioptimus signals engineering maturity and collaborative skills.

| Target Repo | Contribution Idea | Effort |
|---|---|---|
| `squidpy` | Add EMT spatial autocorrelation function | 3–5 days |
| `scanpy` | Tutorial: wound healing scRNA-seq walkthrough | 2–3 days |
| `scvi-tools` | Bug fix or documentation improvement | 1–2 days |
| `anndata` | Performance improvement or edge case fix | 1–2 days |
| `HEST` | Add a new tissue type benchmark | 3–5 days |

**Strategy:** Start with documentation PRs (easy to merge), then move to code contributions. Even 1 merged PR is a signal.

---

### Thought Leadership / Writing
| Format | Topic | Platform | Impact |
|---|---|---|---|
| Blog post | "What wound healing taught me about cancer invasion" | Medium / Substack | Shows biological thinking |
| Technical post | "Fine-tuning scGPT for EMT classification: a practical guide" | Towards Data Science | Shows ML depth |
| bioRxiv preprint | Multi-cancer EMT atlas (project E1) with cross-dataset comparison | bioRxiv.org | Academic credibility |
| Twitter/X thread | "I used @Bioptimus H-Optimus to explore TME — here's what I found" | X (Twitter) | Direct company visibility |
| GitHub README | Flagship project with clear bio motivation → methods → results | GitHub | Portfolio centerpiece |

**Key insight:** Xavier Puig (Bioptimus co-founder) and team actively post on X. A thoughtful thread using their model will get noticed.

---

### Updated Recommended Project Order (with new projects)

```
Month 1 (Build Foundation)
├── E2: H-Optimus TME Explorer ←── Start here! Uses their model directly
├── E1: Multi-Cancer EMT Atlas ←── Leverages your expertise
├── N6: scVI Deep Generative Model ←── Quick win, shows ML maturity
└── Learn: Spatial transcriptomics fundamentals

Month 2 (Go Deeper)
├── M1: Spatial EMT Mapping ←── Visium/Xenium, direct STELA connection
├── M2: Immunotherapy Response Predictor ←── Your clinical expertise shines
├── N1: scGPT Fine-Tuning ←── Foundation model experience
└── Open source: 1 PR to squidpy or scanpy

Month 3 (Portfolio Centerpiece)
├── H1: Histology-to-Transcriptomics Bridge ←── THE key project
├── N2: Perturbation Prediction (GEARS) ←── Cutting-edge
├── N3: Multi-Omic scRNA + scATAC ←── New data modality
└── Write: bioRxiv preprint from E1 results

Month 4 (Advanced / Differentiation)
├── N4: GNN for Gene Regulatory Networks ←── Rare skill
├── H2: Multimodal Cancer Platform ←── Full-stack AI-bio
├── N5: Clinical NLP Pathology Mining ←── Unique angle
└── H3: Clinical Trial AI Agent ←── If targeting senior roles
```

---

### Updated GitHub Portfolio Structure

```
github.com/rahulsarate/
├── scRNA-seq-for-tissue-fluidity/     ← existing (wound healing + EMT + agents)
├── cancer-emt-atlas/                   ← E1: Multi-cancer EMT dashboard
├── h-optimus-tme-explorer/             ← E2: Using Bioptimus's model
├── spatial-emt-cancer/                 ← M1: Spatial transcriptomics  
├── immunotherapy-response-ml/          ← M2: Clinical ML
├── histology-transcriptomics-bridge/   ← H1: THE flagship project
├── scgpt-emt-finetuning/              ← N1: Foundation model fine-tuning
├── perturbation-prediction-emt/        ← N2: GEARS/CPA perturbation biology
├── multiome-emt-regulatory/            ← N3: scRNA + scATAC integration
└── grn-gnn-wound-healing/             ← N4: GNN on gene regulatory networks
```

---

### Additional Companies to Target

| Company | Focus | Your angle |
|---|---|---|
| **Sanofi Digital** (Paris) | AI/ML for drug discovery + spatial bio | Paris connection + spatial transcriptomics |
| **Novo Nordisk Digital Science** | scRNA-seq in metabolic disease | EMT in fibrosis is directly relevant |
| **BioNTech Bioinformatics** | mRNA + immune TME analysis | Immunotherapy background + TME prediction |
| **Cellarity** (Cambridge MA) | "Cell as the drug" — perturbation + ML | N2 (perturbation prediction) directly relevant |
| **Insitro** | ML-driven drug discovery, scRNA-seq core modality | Full single-cell + ML portfolio |
| **Flagship Pioneering** | Creates biotech startups | Early-stage biotech founding path |
| **EBI / Wellcome Sanger** (UK) | Top academic single-cell center | Academic springboard to industry |

---

*Generated: April 2026 | Updated: April 17, 2026 — added N1–N6 projects, open source strategy, writing plan*
